虽然高效抗逆转录病毒治疗已经把艾滋病变成了能够长期管理的慢性传染病，可是患者预后的个体差异比较明显。近些年不良环境暴露被发现是影响艾滋病生存质量、免疫重建、疾病进展的重要外源性因素。环境污染物作为广泛存在而且有可预防的外部风险因素，有着低剂量、长时程、多途径暴露的特点，能够通过免疫毒性、氧化应激、慢性炎症激活、代谢紊乱等多种通路，干扰艾滋病患者的免疫重建进程和病毒抑制效果，进而影响其疾病进展、远期生存结局。本文系统综述了大气污染物、重金属、黄曲霉素、多环芳烃等典型环境污染物与艾滋病患者发病进展及预后转归的关联，深入分析人群易感性差异和当前研究存在的局限，可为优化HIV/AIDS患者的健康管理策略、降低环境相关健康风险、改善患者远期预后给予理论参考和实践依据。

Although highly active antiretroviral therapy has turned AIDS into a chronic infectious disease that can be managed for a long time, the individual differences in the prognosis of patients are obvious. In recent years, adverse environmental exposure has been found to be an important exogenous factor affecting the quality of life, immune reconstruction and disease progression of AIDS. As an external risk factor that exists and has potential intervention, environmental pollutants have the characteristics of low-dose, long-term and multi-channel exposure. They can interfere with the immune reconstruction process and virus inhibition effect of AIDS patients through various pathways such as immunotoxicity, oxidative stress, chronic inflammation activation, and metabolic disorders, thereby affecting their disease progression and long-term survival outcomes. This article systematically reviews the association between typical environmental pollutants such as air pollutants, heavy metals, aflatoxins, and polycyclic aromatic hydrocarbons and the progression and prognosis of AIDS patients. In-depth analysis of the differences in population susceptibility and the limitations of current research can provide theoretical reference and practical basis for optimizing the health management strategies of HIV / AIDS patients, reducing environmental-related health risks, and improving the long-term prognosis of patients.

目的 探讨剖宫产围术期患者采用布托啡诺治疗寒战的最佳剂量。方法 选取2019年10月—2020年11月期间于本院分娩的150例剖宫产妇女作为研究对象,按照随机数字表法分为A组、B组、C组,各组50例。A组给予0.01 mg/kg布托啡诺静脉注射,B组给予0.02 mg/kg,C组给予0.03 mg/kg。比较3组临床疗效、血流动力学、镇静(Ramesay)评分、不良反应、新生儿Apgar评分。结果 3组治疗有效率、 血流动力学、T₁、T₂时间段Ramesay评分及1 min、5 min、10 min 新生儿Apgar评分比较,差异无统计学意义(P＞0.05);C组不良反应发生率高于B组与A组(P＜0.05);T₃时间段Ramesay评分C组＜B组＜A组(P＜0.05)。结论 0.02 mg/kg剂量布托啡诺治疗剖宫产围术期寒战效果最为理想,产妇围术期血流动力学稳定,不良反应较轻,且对新生儿无明显影响。

Objective To investigate the optimal dose of butorphanol in the treatment of shivering in patients underwent cesarean section. Methods A total of 150 women with cesarean section in our hospital from October 2019 to November 2020 were selected as the research objects, and were divided into group A, group B and group C according to random number table method, with 50 cases in each group. Group A was given 0.01 mg/kg butorphanol intravenously, group B was given 0.02 mg/kg, and group C was given 0.03 mg/kg. Clinical efficacy, hemodynamics, sedation (Ramesay) scores, adverse drug reactions (ADR) and neonatal Apgar scores were compared among the three groups. Results There were no significant differences in effective rate, hemodynamics, Ramesay scores at T₁ and T₂ time periods and Apgar scores of neonates at 1 min, 5 min and 10 min among the three groups (P>0.05). The incidence of ADR in group C was higher than that in group B and A (P<0.05). Ramesay score at time of T₃ of group C was lower than group B and group A (P<0.05). Conclusion The 0.02 mg/kg dose of butorphanol in the treatment of perioperative shivering in cesarean section was the most ideal dose, perioperative hemodynamics of puerpera was stable, adverse reactions were mild, and there was no obvious influence on neonates.

目的 探讨蛛网膜下腔注射布比卡因与舒芬太尼预防剖宫产术中寒战效果的影响。方法 选取我院拟行剖宫产手术的产妇158例随机分为对照组(n=79)和观察组(n=79),两组均行蛛网膜下腔注射麻醉下的剖宫产术,对照组给予麻药为质量浓度为5 g/L的布比卡因,观察组为质量浓度为5 g/L的布比卡因+小剂量舒芬太尼,观察两组术中预防寒战效果。结果 观察组寒战发生率(16.64%)低于对照组(39.25%)(P<0.05);MAP、HR组内各时间点间有差异(P<0.05),组间同时间点比较无差异(P>0.05);观察组牵拉痛程度轻于对照组(P>0.05);两组新生儿1min Apgar评分和5min Apgar评分无差异(P>0.05);观察组产妇不良反应发生率为6.33%,与对照组的12.66%比较,无差异(P>0.05)。结论 剖宫产术进行蛛网膜下腔注射布比卡因和舒芬太尼,对预防产妇术中寒战的效果的具有积极影响。

目的 了解河源市无偿献血人群中丙型肝炎病毒(HCV)感染情况及HCV感染合并乙型肝炎病毒(HBV)、人类免疫缺陷病毒(HIV)以及梅毒螺旋体(TP)感染的情况,为当地预防和控制输血传播性疾病提供实验室依据。方法 选择2010年1月1日—2015年12月31日河源市中心血站无偿献血者71 618例,采用酶联免疫吸附试验(ELISA)方法检测其血浆抗-HCV、乙型肝炎表面抗原(HBsAg)、抗-TP及HIV(Ag/Ab),统计分析抗HCV阳性无偿献血者合并感染HBV、HIV和TP的情况。结果 71 618例无偿献血者标本中抗-HCV、HBsAg 、抗-TP及HIV(Ag/Ab) 阳性率分别为0.56％(402例)、1.48％(1 062例)、1.14％(821例)、0.09％(61例);初次献血者抗-HCV、HBsAg 、抗-TP及HIV(Ag/Ab)阳性率均高于多次献血者(P＜0.05);402例抗-HCV阳性无偿献血者中合并HBsAg、抗-TP、HIV(Ag/Ab) 阳性率分别为1.74%(7例)、4.98%(20例)、0.25%(1例)。结论 抗-HCV阳性献血者合并TP感染率显著高于抗-HCV阴性无偿献血者, HCV合并HBV、HIV感染率低。

目的 调查广州市在校大学生AIDS相关知识及对HIV感染者态度现状,为学校更有效地开展大学生AIDS健康教育提供依据。方法 采用目的抽样方法,对广州市某高校 1200名在校大学生进行关于AIDS相关知识、态度的问卷调查。结果 不同年级、生源地,AIDS相关知识差异均有统计学意义(P值均＜0.01);多数学生对HIV感染者持积极态度,但仅5.73%的学生愿意与HIV感染者共餐;2.70%愿意与感染HIV的同学同住一个寝室。网络是大学生获取AIDS相关知识的最主要途径。结论 大学生AIDS相关知识知晓率水平较高,但缺乏系统性和全面性;多数学生对HIV感染者持积极态度,但是一旦与自我卷入较深,即表现出对HIV感染者的回避甚至歧视。高校应加强对大学生AIDS健康教育的系统性、全面性和深刻性,以消除对AIDS的心理恐惧,达到对HIV感染者的零歧视。

Objective To investigate the AIDS related knowledge of the Guangzhou undergraduates and the attitudes on HIV infection status, for the school to provide basis for AIDS health education and to carry out AIDS health education during college students more effectively. Methods 1200 college students in a university in Guangzhou were surveyed by a questionnaire on HIV/AIDS related knowledge and attitudes, using the way of purposive of sampling. Results There was statistical significant difference on the AIDS-related knowledge in the different grades and origin of students (P<0.01). The majority of students has a positive attitude to the HIV-infected, but only 5.73% of them wer willing to share a meal with HIV-infected persons, and 2.70% of them were willing to live with HIV-infected. The network is the most important way to access to HIV/AIDS related knowledge for college students. Conclusion The level awareness during college student on AIDS-related knowledge is high, but lack of systematic and comprehensive. The majority of students had a positive attitude towards the HIV-infetected, however once self-involved, they may avoid even discriminate the HIV-infected individuals. Therefore, the universities should strengthen AIDS health education of college students comprehensively and profoundly, in order to eliminate fear of AIDS, and reached zero discrimination HIV-infected persons in the future.